Captopril NEW
| Price | $40 | $48 | $59 |
| Package | 50mg | 100mg | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Captopril | CAS No.: 62571-86-2 |
| Purity: 99.88% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Captopril |
| Description | Captopril (SA333) is a potent and specific inhibitor of peptidyl-dipeptidase A. It blocks the conversion of angiotensin I to angiotensin II, a vasoconstrictor and important regulator of arterial blood pressure. |
| Kinase Assay | Binding assay: Cells are plated in 24-well plates and cultured until confluence. Before the experiment, the cells are washed three times with 0.5 mL per well of DMEM at room temperature. After removal of the medium, 400 μL binding DMEM is added and the plate is then left for 15 min at 37 ℃. For saturation binding assays cells are incubated with increasing concentrations [3H]Candesartan (final concentrations between 0.15 nM and 15 nM) in a final volume of 0.5 mL at 37 ℃ for 5 min to 180 min. For competition binding assays 50 μL of buffer or 50 μL of buffer containing increasing concentrations of unlabelled Candesartan is added. After 30 min, 50 μL of buffer containing [3H]Candesartan (final concentration 1.1 nM) or [3H]Candesartan (final concentration 1.0 nM) is added, and the cells are further incubated for 30 min at 37 ℃. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 21.7 mg/mL (100 mM) DMSO : 50 mg/mL (230.11 mM) |
| Keywords | antihypertensive | Angiotensin-converting Enzyme (ACE) | Captopril | failure | SQ 14534 | inhibit | oral | SQ14534 | congestive | hypertension | Inhibitor | SA 333 | SQ14225 | SQ-14225 | SA-333 | heart |
| Inhibitors Related | Tranilast | Enalapril Maleate | Sacubitril/Valsartan | Irbesartan | Losartan | Ramipril |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-19 | |
| $5.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $0.00/25kg |
VIP1Y
|
Hebei Mojin Biotechnology Co.,Ltd
|
2024-07-25 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-10 | |
| $35.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-17 | |
| $80.00/1KG |
Anhui Yisheng Technology Co., LTD
|
2023-01-12 | ||
| $80.00/1KG |
XINGTAI XINGJIU NEW MATERIAL TECHNOLOGY CO., LTD
|
2021-12-29 | ||
| $100.00/1KG |
Qiuxian Baitai New Material Co., LTD
|
2021-11-26 | ||
| $350.00/1Kg/Bag |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2021-10-08 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY